Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Zogenix has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners across 2 art units, so prosecution requires coordination across distinct technical assignments.
BORI, IBRAHIM D is the busiest examiner, with 2 pending matters. Reviewing those related matters together may support consistent claim strategy, while the remaining assignment should receive its own examination-specific analysis.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 2 | 43.9% | +39.0% |
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17899942 | NORFENFLURAMINE TO TREAT DRAVET SYNDROME | BAEK, BONG-SOOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18418133 | METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE | BORI, IBRAHIM D | 146d overdue |
| 18418121 | METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE | BORI, IBRAHIM D | 85d overdue |
| 17899942 | NORFENFLURAMINE TO TREAT DRAVET SYNDROME | BAEK, BONG-SOOK | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18418133 | METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE | BORI, IBRAHIM D | 1629 | §103Other | Final Rejection | 146d overdue | Pending | Jan 19, 2024 |
| 18418121 | METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE | BORI, IBRAHIM D | 1629 | §103Other | Final Rejection | 85d overdue | Pending | Jan 19, 2024 |
| 17899942 | NORFENFLURAMINE TO TREAT DRAVET SYNDROME | BAEK, BONG-SOOK | 1611 | §102§103 | Non-Final OA | — | Pending | Aug 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZogenix has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Ibrahim D Bori has the most, with 2 of Zogenix's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
